Use access key #2 to skip to page content.
$12.30 -1.38 (-10.09%)
10/10/2008 4:00 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating:
**

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

View All Commentary (AMLN)

Recs

0

Avatar nepedal (63.09) Submitted: 9/21/06 5:29 PM : Outperform Start Price: $45.66 AMLN Score: -39.92

Byetta is the real deal in diabetes treatment. Everything else in this company (and there's some) is gravy to an investor. As all paradigmatic shifts, Byetta will take time but I think it'll be worth the wait.

Report this Post Replies: 0 | Reply

Featured Broker Partners